Predictors for change to thiazolidinedione prescribing in the UK following the rosiglitazone cardiovascular safety warning
Résumé
Objective To investigate switching from thiazolidinediones, and predictors for switching treatment, after publication of a meta-analysis reporting an increased risk of myocardial infarction associated with rosiglitazone use. Research design and methods Using THIN UK primary care database, the number of people with Type 2 diabetes prescribed either thiazolidinedione; rosiglitazone (n=10,062) or pioglitazone (n=4,454) and the rate of switching from thiazolidinediones (n=3,301 and 1,106 respectively), were computed for each month, May 2006 to January 2008. The probability of switching post-publication, May 2007 to January 2008, was modelled by logistic regression in a forward stepwise model. Variables included demographics, history of ischaemic heart disease (IHD), heart failure (HF) or stroke, risk factors for IHD, glucose-lowering and cardiovascular drug use, HbA1c and diabetes duration. Results There was a sharp increase in switching from both thiazolidinediones in summer 2007; rosiglitazone prescription numbers then decreased while pioglitazone prescribing increased. Switching from rosiglitazone was associated with IHD (adjusted odds ratio OR 1.72; 95% confidence intervals CI 1.47-2.00), insulin treatment (OR 5.10; 95% CI 3.21-8.10), HF (OR 2.26; 95% CI 1.62-3.18), recent sulphonylurea prescription (OR 1.33; 95% CI 1.17-1.51) sex (OR males v females 0.79; 95% CI 0.70, 0.90) and duration of therapy. Switching from pioglitazone was associated with HF (OR 3.05; 95% CI 1.77-5.26), duration of therapy, and number of glucose lowering treatments. Conclusions Prescribing habits for both thiazolidinediones changed immediately following the safety warning. IHD was associated with switching from rosiglitazone; otherwise reasons for change appear to be complex, not directly related to the findings of the meta-analysis.
Fichier principal
PEER_stage2_10.1111%2Fj.1742-1241.2011.02648.x.pdf (334.4 Ko)
Télécharger le fichier
Origine : Fichiers produits par l'(les) auteur(s)
Loading...